Amarin Corp Plc (AMRN)

[irishpaddy]

For the first time ...Amarin have the less to lose in this case, the asymmetry of risk reward is firmly in Amarins favor.

If this case goes to trial it will no longer be about Vascepa for Hikma, it will be about every generic drug they market and how they label it and how they get around patent protections and that has every generic company worried.
But its even more difficult for Healthnet if they risk going to trial and lose then every insurer will then realise that they must now take action to ensure that every drug they cover does not favor generic over brand patent.

If either party loses in a trial the costs re Amarin will fade in significance to the future costs of every drug sold by every generic company and every drug covered by every insurance company.

Hikma and Healthnet may just have walked into the biggest mistakes ever made.